MedTrace Logo

A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes

NCT01541631 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2012-03-05

No results posted yet for this study

Summary

In this study, it is hypothesized that helminth infections modulate immune responses against HIV-1 infection resulting into increased HIV-1 multiplication, faster progression to AIDS and increased episodes of AIDS-related opportunistic infections. Furthermore, the effect of helminth infections on progression of HIV-1 infection is dependent on helminth infection intensity, host background immunity, nutritional status, demographic factors and socio-economic status. Also, treatment of helminth infections using praziquantel and albendazole among HIV-1 infected individuals will lead to reduction in HIV-1 viral loads, improvement of CD4+ counts, CD4+/CD8+ ratio and Hb levels, improved weight gain and reduction of episodes of HIV-1 related opportunistic infections. In addition, HIV-1 infection is associated with poor anthelminthic treatment outcome as compared to non-HIV infected individuals

Conditions

  • Anemia
  • Intestinal Helminthiasis
  • Intestinal Schistosomiasis
  • Human Immunodeficiency Virus I Infection
  • Hematologic Diseases
  • Opportunistic Infections

Interventions

DRUG

Praziquantel and Albendazole

Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once

DRUG

Praziquantel and Albendazole

Praziquantel- 40mg/kgBWT Albendazole - 400mg once

DRUG

Praziquantel and Albendazole

Praziquantel- 40MG/KG ONCE Albendazole - 400mg once

Sponsors & Collaborators

  • National Institute for Medical Research, Tanzania

    collaborator OTHER_GOV

  • University of Cambridge

    collaborator OTHER

  • Catholic University of Health and Allied Sciences

    lead OTHER

Principal Investigators

  • Humphrey D Mazigo · Makerere University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01541631 on ClinicalTrials.gov